Russian patents in English sorted by IPC


Method for immune correction with api-phytocomposition

Immune deficiency is modulated in laboratory animals by single cyclophosphan administration in a dose of 200 mg/kg of body weight (the first day of an experiment). The immune deficiency is corrected by an api-phytocomposition in the form of an aqueous suspension of honey, pollen, propolis, purple Echinacea extract in a ratio of 10:1:1:2. The composition is administered into the laboratory animal intragastrically (through a probe) in a dose of 200 mg/kg daily for 10 days on the second day of the experiment.

Measuring device for analysis of biological fluids

Set of inventions relates to measurement of volume or concentration of biological matters. Proposed measuring device comprise casing and at least one display integrated therein. Note here that said casing comprises compartment for fitting the cartridge in said casing to fit specimen to be measured. Note also that said compartment has hole made at casing front. Note that casing first part for cartridge to be fitted therein extends at the angle to casing second part. Besides, this invention covers the method of measurement with the use of described device in analysis of biological fluids.

Health-improving composition for administration in form of drops and such composition production method

Invention relates to functional food products and represents a method for production of a non-aqueous health-improving product that is administrated in the form of drops and contains strain of lactic bacteria suspended in vegetable food oil; vegetable food oil is mixed with vitamin D; Lactobacillus rhamnosus GG lactic bacteria are suspended in the produced oil mixture.

Method for treatment of skin aging and scars

Group of inventions relates to medicine, namely to cosmetology, and can be used for treatment of skin aging. For this purpose, used is a medication, which contains a basic fibroblast growth factor (bFGF) as a single active ingredient, which is introduced intracutaneously or subcutaneously into the place of a scar or into the surrounding region, for instance, a keloid, a hypertrophic scar and a scar contracture; in addition, the medication is also intended for treatment of one or more types of skin aging, selected from the following list: skin wrinkles, sagging skin, rough skin, skin thinning and reduction of skin resilience and elasticity because of rupture of dermal tissues or reduction of functions of fibroblast cells, with skin aging being photoaging, and a value of a dose of the basic fibroblast growth factor (bFGF) constituting from 0.1 mcg to 1 mg per 1 cm2 of skin, which represents the treatment target.

Multicomponent bioactive nanocomposite coating with antibacterial effect

Coating is based on titanium carbonitride with addition of additional elements which provide the required set of mechanical and tribological properties, as well as biologically active and antibacterial properties. Overall concentrations of basic and additional elements are in the following ratio: 1,2 < ∑ X i ∑ Y j < 20, where Xi is the overall concentration of basic elements Ti, C, N in the coating, Yj is the overall concentration of additional elements Ag, Ca, Zr, Si, O, P, K, Mn in the coating.

Method for correction of thrombophilic disorders accompanying pregnancy

Haemostatic values, endothelial dysfunction characteristics, diagnosed genetic forms of thrombophilia and habitual miscarriage are detected; the detected disorders are assessed in points depending on the gestational age. That is followed by calculating the total score, and therapy is prescribed depending on the total score. The case follow-up involves changing the therapeutic regimen with the total score variations.

Method of production of soluble complex preparations from water-insoluble substances of medicinal products

Method of production of water-soluble polymer anthelmintic preparations from water-insoluble substances is characterised in that the anthelmintic substance and polyvinylpyrrolidone with a low molecular weight with Mw of 12700±2700 in gram equivalent ratio of 70:30 is taken and stirred thoroughly under draft in a mortar or in a chemical reactor with a mixer of any type for 10-30 minutes, adding gradually to the mixture 40-70 parts by weight of acetone or ethyl alcohol per 100 parts by weight of the mixture of polyvinylpyrrolidone and anthelmintic substance, the obtained homogeneous mass is dried and milled to form the powder with 70% of particle size less than 5-9 mcm.

Pharmaceutical composition in form of solution for injection and method for production thereof

Invention discloses a pharmaceutical composition in the form of a solution, having nootropic and neuromodulating activity, characterised by that it contains N-carbamoylmethyl-4-phenyl-2-pyrrolidone as an agent, hydroxyethyl starch as an auxiliary substance and water for injection. The invention also relates to a method of producing such a pharmaceutical composition, which includes adding hydroxyethyl starch to the water for injection which is preheated to 85-90°C and mixing until complete dissolution, adding N-carbamoylmethyl-4-phenyl-2-pyrrolidone powder and mixing at temperature of 75-85°C until complete dissolution, adding water for injection to obtain the end volume of the solution and mixing once more, holding the obtained solution for 35-40 minutes at temperature of 75-85°C, cooling to 20-30°C, sterilising by filtering through filters with pore diameter of 0.22 mcm and packing in ampoules, which are further sterilised for 8 minutes at temperature of 120°C.

Method of predicting onset of pregnancy

Invention relates to medicine, in particular to laboratory diagnostics, and can be used for the determination of a high thrombogenic risk in pregnant women in case of performing extracorporal fertilisation in blood plasma. Essence of the method: peak concentration of thrombin in a test of thrombin generation is determined and if its value is higher than 360 nmol/l, a pregnant woman is referred to a group of a high thrombogenic risk and 2-3 days before performing a puncture of ovarian follicles heparin therapy is carried out.

Method for producing microspheres for preparing injectable dosage form of diclofenac, composition and dosage form

Microspheres contain diclofenac in the form of an acid included in a matrix of a biodegradable polymer specified in a group consisting of polylactide and polylactide-co-glycolide; an average size of microspheres falls within the range of 5 to 150 mcm; a degree of diclofenac inclusion makes 5-50%, and the said microspheres release 60 to 95% diclofenac for 14 days.

Method of post-surgical treatment of cerebral tumour

For the purpose of post-surgical treatment of cerebral tumours, memantine is prescribed in a dose of 10 mg daily for 5-7 days before radiation therapy, and in a dose of 20 mg during radiation therapy 4-6 hours before the radiation session. On completing the course of radiation therapy, memantine is prescribed in patients aged up to 60 years old in a dose of 10 mg for 2-3 months daily, in patients aged 60 and older in a dose of 20 mg for 5-6 months daily.

Method of treating endogenous intoxication syndrome caused by hyperproteolysis

Antiproteolytic preparation Ambene in a dose of 50-250 mg is introduced intravenously by the stream infusion for at least three days every 3-4 hours in a combination with heparin. Heparin is introduced subcutaneously is a dose of 250 units 4 times a day.

Method of evaluating quality of mineral-based soap grease during prolonged storage in sealed container

Initial values of the most information bearing quality factors of the grease are determined. Containers with grease are placed into a climatic heating and cooling chamber. A 24 hour cycle, during which temperature is measured from minus 60°C to 60°C is taken as one year of storage. After each cycle, values of factors identical to the initial values are determined in said heating and cooling chamber. The value of each of said factors corresponding to a year of storage in natural conditions is calculated using a given formula using given software. Testing continues for values of factors within the range of allowable values and if at least one of the factors obtained by calculation deviates from the allowable value, the shelf life of the grease is taken to be the number of years numerically equal to the number of cycles preceding the change in the quality factors which does not correspond to standards.

Orally soluble and/or effervescent compositions, containing at least one s-adenosylmethyonine (sam)

Claimed invention relates to a pharmaceutical, dietary, nutritional orally soluble composition for peroral intake, which contains at least one S-adenosylmethyonine (SAMe) salt in a combination with physiologically acceptable excipients and optionally other active ingredients. The physiologically acceptable excipients include light magnesium oxide.

Implanted products, containing nanoparticles

Invention relates to the application of a solid medicinal product, which is heated under the impact of an alternating magnetic field, for further therapeutic treatment after surgical ablation of tumours and cancerous ulcers. The medicinal product represents a surgical implant, presented in the form of a physiologically acceptable fabric, sponge or film. The medicinal product contains magnetic particles, which generate heat when excited by an impact of the alternating magnetic field, and in this way, heat the medicinal product.

Method of preparing anti-inflammatory veterinary ointment

Method of preparing the anti-inflammatory veterinary ointment for outward application consists in mixing while heating to the temperature of 40-50°C in the reactor of molten petrolatum, pine oleoresin, chlorophyll-carotene paste until homogenous consistency, then glycerine and olive oil is fed portionwise with continuous stirring, after which again mixing of the components is carried out for 10-30 minutes until the homogeneous mass, the resulting ointment is cooled and packaged, at that the components of the mixture are taken in the following ratio, wt %: pine oleoresin 3.0; chlorophyll-carotene paste 3.0; petrolatum 69.0; glycerine 5.0; olive oil 20.0.

Modular device for aromatisation

Set of inventions relates to air aromatisation. Proposed device comprises multiple modular units accommodating scented matter sprayer unit incorporating multiple rechargeable sprayers and control unit. Said sprayer units are combined to produce a mosaic of scents. Note here that control unit is configured to control aromatisation device so that sprayer unit forms the spatial-time composition of scented matter and removes said formed composition. Set of inventions relates to method of control over aforesaid device.

Method of detecting degenerative muscular diseases and method of determining therapeutic efficiency in case of diseases

Invention relates to a method of early detection of muscular degenerative diseases and to a method of prediction and/or determination of a therapeutic efficiency of a therapeutic preparation and/or a method of disease therapy by measurements of tetranor-PGDM (11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid) in a subject's urine sample and comparison of its content relative to a sample, separated from a healthy individual. A muscular degenerative disease is identified in a patient if the concentration or content of tetranor-PGDM in a sample, separated in the patient is higher than the concentration or content of tetranor-PGDM in a sample, separated from a healthy individual. An efficiency of the therapeutic preparation and/or the method of therapy of the muscular degenerative disease is determined by comparison of the content of tetranor-PGDM in the sample, separated from the patient with the muscular degenerative disease before and after introduction of the therapeutic preparation. If the measured content of tetranor-PGDM in the sample considerably or inconsiderably decreases after the introduction of the therapeutic preparation, the method of therapy is efficient. The invention also relates to a set for diagnostics of muscular degenerative diseases, which includes an antibody to tetranor-PGDM, labelled tetranor-PGDM and optionally, at least, one compound, selected from a group, consisting of an antibody to immunoglobulin, a diluting solution for the sample, a diluting solution for the antibody and labelled tetranor-PGDM, tetranor-PGDM standard of the known concentration, a substrate for an enzyme immunoassay and a stopping solution for the enzyme immunoassay.

Composition for oral application, containing cooling substance

Invention relates to a composition for treating throat pain in the form of dispersible tablets. The claimed composition contains an endothermic cooling substance, representing xylitol, in an amount of 1-10 wt/wt % and an active substance, which contains menthol and 2,4-dichlorobenzyl alcohol and amylmetacresole.

Compositions for treatment of gastroesophageal reflux disease (gerd)

Invention relates to the pharmaceutical industry, in particular to a peroral pharmaceutical composition, which contains polysaccharides from platyclades of Opuntia Ficus Indica, an extract of Olea Europeae leaves, alginate and sodium bicarbonate in a specified ratio. Components of the composition described above act with respect to reduction of gastroesophageal reflux.

Orally disintegrating tablet temazepam compositions

Invention relates to the chemical-pharmaceutical industry and represents an orally disintegrating tablet composition, which includes particles of a therapeutic preparation, containing: a therapeutically effective quantity of, at least, one therapeutic preparation; 0.5-3% ODT binding polymer; sugar alcohol and/or saccharide; and a disintegrant, with particles of the therapeutic preparation being prepared by granulation of, at least, one therapeutic preparation, sugar alcohol and/or saccharide and the disintegrant in the presence of the ODT binding polymer, where the composition mainly disintegrates within approximately 30 seconds after contact with saliva in the oral cavity or in testing by a disintegration test <USP 701>.

Medical connector and its bendable combined lid

Group of inventions relates to medical devices. Claimed is a medical cap, which can be broken off, including the cap body, with the cap body including an upper wall, a side wall and a cavity, in which a rubber stoppering means is placed, with a breaking off element being provided on the upper wall, the said element includes a tubular neck section, connected with the upper wall, and a section which is broken off, connected to the neck section; a brittle hollow is provided on the neck section, and the brittle wall is limited by the brittle hollow and an internal surface of the neck section wall, and the medical combined cap which can be broken off additionally contains an internal cap and the rubber stoppering means, densely held between the cap body and the internal cap. Also described is a medical port, connected with the said cap.

Diagnostic technique for postvaccinal immunity to diphtheria in children living on territory of exposure to hazardous chemical factors

Invention involves the following stages: chemical environmental contaminants targeting the immune system on the territory of residence are listed. For the listed contaminants, a risk of immune disorders is assessed by a hazard index. If HI is more than 1.0, the children living in the specified conditions and vaccinated up to a schedule and/or re-vaccinated with a DPT vaccine - diphtheria and tetanus toxoids and pertussis vaccine - and suffering from no immune diseases are selected. Blood is sampled from the above children; the sample is examined to measure an amount of the specified chemical environmental contaminants to detect individuals with the above amount exceeding an ambient regional level by not less than 20%; an amount of postvaccinal immunoglobulin G (IgG) antibodies to diphtherial anatoxin is measured in the blood serum of the selected individuals by ELISA with specific test-systems. The individuals with the above amount being less than the protective level are selected and assigned with a correlation of the above antibodies from the blood concentration of the listed chemicals, and if stating the reliable relations simultaneously: high blood concentration of lead more than 0.04 mg/dm3 and of o-cresol more than 0 mg/dm3 and lower concentration of postvaccinal IgG antibodies to diphtherial anatoxin as compared to the protective level, a decrease of the postvaccinal immunity to diphtheria is diagnosed in the child.

Antimicrobial/antibacterial medical devices, coated with traditional preparations of chinese medicine

Antimicrobial composition for coating a medical device includes a material, which forms a polymer film, and an antimicrobial preparation from the traditional Chinese medicine, selected from a group: extract of Houttuynia cordata, sodium houttuyfonat and sodium new houttuyfonat or their mixtures. The medical device, covered with an antimicrobial composition, is made in the form of an implanted device.

Method of stimulation of poultry growth

Invention is intended to stimulate the growth of poultry. The growth stimulators are used as amides of formula 1 of palmitic (n=14), stearic (n=16) acids and amide of oleic acid of formula 2 , which are used in the form of salts with pharmacologically acceptable acids.

Method of treatment of calves with simuliidotoxicosis

Method of treatment of calves with Simuliidotoxicosis is that 40% solution of urotropine is administered intravenously to calves at a dose of 1.5 ml per 10 kg of animal body weight.

Method for assessing sensitivity of vascular endothelium to shear stress

Method implies as follows: blood nitrites and endothelin are determined prior to and after an occlusion test. The sensitivity of the vascular endothelium to shear stress is determined by the coefficient index(e) calculated by formula. If the coefficient index(e) is 0.5 or less, the sensitivity of the vascular endothelium to shear stress is considered to be low, while the value index(e) of more than 0.5 shows the normal sensitivity value.

Changing of colour of chalcone-containing preparative forms for oral cavity care

Invention relates to the field of pharmaceutics, in particular represents compositions and methods for the oral cavity care, in which a composition includes chalcone as a colour-changing component, which can represent phenyl-3-methoxy-4-hydroxystyrylketone. The change of colour of the colour-changing component is caused by an addition of saliva and/or change of the composition pH.

Application of apl peptide for treatment of inflammatory intestinal disease and type 1 diabetes

Group of inventions relates to medicine and can be used for treatment of Crohn's disease, ulcerous colitis and type 1 diabetes mellitus. For this purpose applied is APL peptide or its analogues, obtained from a human heat shock protein with a size of 60 kDa (hps60) in order to obtain a pharmaceutical composition. Also claimed are the pharmaceutical composition and the application of a medication for induction of apoptosis of pathogenic clones of T-cells in patients with inflammatory intestinal disease or type 1 diabetes.

Method of identifying compound, suitable for treating inflammatory condition of oral cavity

Invention relates to the field of pharmaceutics and represents a method of identifying a compound, suitable for treatment of gingivitis, which includes an interaction of the first gingival sample, obtained from a mammal, suffering from gingivitis, with an analysed compound; an interaction of the second gingival sample from the oral cavity of a mammal with a positive control - a compound, suppressing the expression of one or more matrix metalloproteinases (halogenated diphenyl ether); measurement of a degree, with which an expression of one or more matrix metalloproteinases is suppressed by means of the analysed compound; measurement of a degree, with which the expression of one or more matrix metalloproteinases is suppressed by means of the positive control; and comparison of a degree, with which the expression of one or more matrix metalloproteinases is suppressed by means of the analysed compound, with a degree, with which the expression of one or more matrix metalloproteinases is suppressed by means of the positive control; in which the analysed compound, which suppresses the expression of one or more matrix metalloproteinases in an equal or a higher degree than the positive control, is a compound, suitable for treatment of gingivitis; where one or more matrix metalloproteinases, for which the expression is measured, include, at least, MMP-9 and MMP-13.

More Russian patents:

2504000 - 2504199

2504200 - 2504399

2504400 - 2504599

2504600 - 2504799

2504800 - 2504999

2505000 - 2505199

2505200 - 2505399

2505400 - 2505599

2505600 - 2505799

2505800 - 2505999

2506000 - 2506199

2506200 - 2506399

2506400 - 2506599

2506600 - 2506799

2506800 - 2506999

2507000 - 2507199

2507200 - 2507399

2507400 - 2507599

2507600 - 2507799

2507800 - 2507999

2508000 - 2508199

2508200 - 2508399

2508400 - 2508599

2508600 - 2508799

2508800 - 2508999

2509000 - 2509199

2509200 - 2509399

2509400 - 2509599

2509600 - 2509799

2509800 - 2509999

2510000 - 2510199

2510200 - 2510399

2510400 - 2510599

2510600 - 2510799

2510800 - 2510999

2511000 - 2511199

2511200 - 2511399

2511400 - 2511599

2511600 - 2511799

2511800 - 2511999

2512000 - 2512199

2512200 - 2512399

2512400 - 2512599

2512600 - 2512799

2512800 - 2512999

2513000 - 2513199

2513200 - 2513399

2513400 - 2513599

2513600 - 2513799

2513800 - 2513999

© 2013-2014 Russian business network - Special Russian commercial information project for world wide. Foreign filing in English.